Metabolic dysfunction-associated steatotic liver disease (MASLD) is a complex condition influenced by various factors, including environmental and genetic factors. The primary outcome is the alteration of free fatty acid and triglyceride metabolism, leading to lipotoxicity, impaired autophagy, chronic inflammation, and oxidative stress. Resveratrol, a polyphenolic compound, has shown promising anti-inflammatory, antioxidant, and anti-lipotoxic activities in liver cells through in vitro and animal studies. It inhibits the NF-κB pathway, activates the SIRT-1 and AMPK pathways, normalizes the intestinal microbiome, and alleviates intestinal inflammation. However, clinical studies have yielded inconclusive results regarding the efficacy of resveratrol in alleviating hepatic steatosis or reducing parameters found in MASLD in human patients. The lack of homogeneity between studies, low bioavailability of resveratrol, and population variability compared to animal models are potential reasons for these inconclusive results. Further extensive trials are needed to establish the effectiveness of resveratrol in MASLD.Metabolic dysfunction-associated steatotic liver disease (MASLD) is a complex condition influenced by various factors, including environmental and genetic factors. The primary outcome is the alteration of free fatty acid and triglyceride metabolism, leading to lipotoxicity, impaired autophagy, chronic inflammation, and oxidative stress. Resveratrol, a polyphenolic compound, has shown promising anti-inflammatory, antioxidant, and anti-lipotoxic activities in liver cells through in vitro and animal studies. It inhibits the NF-κB pathway, activates the SIRT-1 and AMPK pathways, normalizes the intestinal microbiome, and alleviates intestinal inflammation. However, clinical studies have yielded inconclusive results regarding the efficacy of resveratrol in alleviating hepatic steatosis or reducing parameters found in MASLD in human patients. The lack of homogeneity between studies, low bioavailability of resveratrol, and population variability compared to animal models are potential reasons for these inconclusive results. Further extensive trials are needed to establish the effectiveness of resveratrol in MASLD.